Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig). (September 2016) - Stein, E.A.; Sampietro, T.; Santos, R.; Harada-Shiba, M.; Bruckert, E.; Blom, D.; Hovingh, G.K.; Couture, P.; Blaha, V.; Farnier, M.; Descamps, O.; Soran, H.; et al.